16156-55-1

Usage

Uses

Used in Pharmaceutical Industry:
ISO-PENTYLMETHANESULPHONATE is used as a reagent for the synthesis of phosphonate derivatives as ATX inhibitors. This application is significant because it aids in the development of potential treatments for diseases where autotaxin plays a role, such as cancer and various inflammatory conditions.

InChI:InChI=1/C6H14O3S/c1-6(2)4-5-9-10(3,7)8/h6H,4-5H2,1-3H3

Upstream product

• 123-51-3 i-Amyl alcohol 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 75-75-2 methanesulfonic acid 
• 563-45-1 3-Methyl-1-butene 
• 151620-51-8 2,4-dioxo-1-N-(3-methylbut-1-yl)-5-N-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 151620-52-9 3-azido-2,4-dioxo-1-N-(3-methylbut-1-yl)-5-N-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 151620-53-0 3-amino-2,4-dioxo-1-N-(3-methylbut-1-yl)-5-N-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine 
• 935548-48-4 {3-hexadecanoylamino-4-[4-(3-methyl-butoxy)-phenyl]-2-oxo-butyl}-phosphonic acid dimethyl ester 
• 935548-47-3 {3-hexadecanoylamino-4-[4-(3-methyl-butoxy)-phenyl]-2-oxo-butyl}-phosphonic acid dimethyl ester 
• 935548-30-4 2-hexadecanoylamino-3-[4-(3-methyl-butoxy)-phenyl]-propionic acid methyl ester 
• 935548-29-1 2-hexadecanoylamino-3-[4-(3-methyl-butoxy)-phenyl]-propionic acid methyl ester 

Relevant academic research and scientific papers

N2-substituted alkoxy aromatic cyclo-2-aminopyrimidine derivative and application thereof

The invention provides an N2-substituted alkoxy aromatic cyclo-2-aminopyrimidine derivative and application thereof. The N2-substituted alkoxy aromatic cyclo-2-aminopyrimidine derivative comprises anoptical isomer and pharmaceutically acceptable salt thereof. Preliminary pharmacodynamic indication shows that the compound disclosed by the invention has FLT3 inhibitory activity, wherein the proliferation inhibition activity is realized on various leukemia cell strains; moreover, the derivative is effective for multiple mutations of AML, such as internal tandem repeat mutation of a near-membranestructural domain and D835 point mutation of an activated ring in a kinase structural domain and almost has no inhibition effect on c-KIT. The derivative can overcome drug resistance brought by clinical point mutation, can reduce toxic and side effects of bone marrow inhibition, and can be applied to preparation of antitumor drugs. The general structural formula of the derivative is shown in thespecification.